doi:http://formularyjournal.modernmedicine.com/node/125395An experimental diabetes drug, TAK-875, demonstrated its ability to improve blood-sugar control with a low risk of hypoglycemia, according to phase 2 study results published online February 27 in The Lancet.Formulary s...
Dr James Garner, General Manager for TGRD Asia said, "We are very pleased and excited that the TAK-875 study has entered Phase III trials in this region. The data published inThe Lancetis very encouraging and TAK-875 is a potential therapy for the treatment of type 2 diabetes in the fut...
Variant calling was performed using Strelka2 v2.9.10, Lancet v1.1.0, GATK v4.1.8.0 Mutect2, VarDictJava 1.7.0, and Octopus v0.603-beta. Final somatic SNVs were called by at least 2 out of 5 callers. CNVs were predicted with GATK v4.1.8.0 CNV. SVs were predicted using Manta v1.6...
TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial . Lancet . 2012; 379 :1403–1411Burant C. F., Viswanathan P., Marcinak J., Cao C., Vakilynejad M., Xie B., Leifke E. (2012) TAK-875 versus placebo ...
Lancet 379:1403-1411Burant CF, Viswanathan P, Marcinak J, et al. (2012) TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 379, 1403- 1411.Burant CF, Viswanathan P, Marcinak J, Cao C, Vakilynejad ...